New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
Tools›Compare›VIP vs PT-141 (Bremelanotide)

VIP vs PT-141 (Bremelanotide)

Side-by-side comparison of key properties, dosing, and research.

Immune SupportSleep Optimization
VIP
Sexual Health & Libido
PT-141 (Bremelanotide)
Summary
VIP is a 28-amino acid neuropeptide with profound anti-inflammatory, vasodilatory, and immunomodulatory effects. It plays a critical role in gut motility, circadian rhythm, and immune tolerance. Used therapeutically for CIRS (Chronic Inflammatory Response Syndrome), MCAS, and inflammatory conditions.
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Half-Life
~2 minutes in plasma (rapidly degraded by peptidases); intranasal delivery may extend local CNS effects
2–3 hours
Admin Route
Intranasal, SubQ, IV
SubQ
Research
—
—
Typical Dose
50 mcg (4 sprays of 12.5 mcg each)
0.5–1.75 mg
Frequency
4x daily
As needed (not daily)
Key Benefits
  • Potent anti-inflammatory for CIRS and mold illness
  • Improves pulmonary hypertension symptoms
  • Regulates gut motility and IBS symptoms
  • Modulates circadian rhythm and sleep quality
  • Reduces mast cell activation (MCAS)
  • Improves cognitive function in neuroinflammatory conditions
  • Vasodilatory — reduces vascular resistance
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
Side Effects
  • Facial flushing (transient, intranasal)
  • Mild nausea
  • Headache at initiation
  • Hypotension at high doses
  • +1 more
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
Stacks With
—
—